相关实验视频
Updated: Sep 9, 2025

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
通过MAT2A-AdoMetDC轴上调聚胺合成的SUMO E1共价基抑制剂
Shuai Zhang1, Jinzhu Li1, Zhiying Wang1
1Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Wuhan 430068, China; Hubei Key Laboratory of Industrial Microbiology, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China.
我们发现了新型的SUMO E1共价抑制剂 (CAI),这些抑制剂会破坏蛋白质SUMOylation,并意外地促进聚胺合成. 结合这些CAI与多胺抑制剂,对癌细胞产生协同作用.
科学领域:
- 生物化学
- 药理学
- 癌症生物学
背景情况:
- 蛋白质SUMOylation失调与各种疾病有关.
- SUMOylation 抑制剂是一种有前途的治疗策略.
- 针对SUMO E1提供了一个调节SUMOylation的潜在方法.
研究的目的:
- 进行第一个虚拟查SUMO E1共价异构抑制剂 (CAI).
- 识别具有独特支架和共价弹头的新型SUMO E1 CAI.
- 研究这些CAI对SUMOylation途径和下游细胞过程的影响.
主要方法:
- 虚拟查SUMO E1共价抑制剂.
- 生物化学测试以评估SUMOylation途径的干扰.
- 甲氨基转移酶的分析 MAT2A SUMOylation.
- 研究聚胺合成的调节.
- 基于细胞的测试评估了聚胺合成抑制剂的协同作用.
主要成果:
- 确定了两个新的SUMO E1 CAI与新的支架和共价弹头.
- 证明这些CAI有效地扰乱了蛋白质SUMOylation.
- 显示MAT2A SUMOylation的抑制意外地刺激了聚胺合成.
- 观察到SUMO E1 CAI和聚胺合成抑制剂对T47D细胞的协同作用.
结论:
- 这项研究为SUMO E1 CAI提供了首次具有成本效益的虚拟选.
- 降低MAT2A SUMOylation的调节可以增强聚胺的合成.
- SUMO E1 CAI可以与多胺合成抑制剂协同作用,提供潜在的治疗组合策略.
- 这项研究提供了关于SUMOylation,共价/全药物开发和多胺代谢的宝贵见解.
更多相关视频
08:55Facile Protocol for the Synthesis of Self-assembling Polyamine-based Peptide Amphiphiles PPAs and Related Biomaterials
Published on: June 25, 2018
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
相关概念视频
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
GPCRs Regulate Adenylyl Cylase Activity
Allosteric Regulation
Drugs Affecting Neurotransmitter Synthesis